65 /100
HIGH RISK
Score updated Jul 14, 2026

TXMD — TherapeuticsMD, Inc. Dilution Risk Tracker

Track TXMD dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track TXMD — Get alerts when the score changes →

As of July 14, 2026, TherapeuticsMD, Inc. (TXMD) has a DilutionWatch DilutionScore of 65/100, rated HIGH dilution risk. TherapeuticsMD, Inc. has a market capitalization of $24.77M, 11.57M shares outstanding, 51 institutional holders tracked. Key dilution vectors include 6.53M outstanding warrants, approximately 1 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
95
📊 Float Risk
27
⚠️ Warrant Exposure
90
🔄Convertible Debt

🌦️ Dilution Forecast

⛈️
Warning
High probability of dilution event
52%
📜 Warrant Exercise 60%
• Massive warrant overhang: 56% of shares outstanding
• Warrant risk score very high (90/100)
💰 Capital Raise 55%
• Critical: only 0.6 months cash remaining
🔄 Reverse Split 30%
• 52-week low $0.98 has breached $1
• Only 1 months cash — financial pressure
🔔 Track TXMD — Get forecast alerts →

💹 Market Data

Market Cap$24.77M
Shares Outstanding11.57M
Float9.49M
Cash$5.75M
Debt$93.60M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 25.5% shares (2026Q1 vs prior)
51 institutional holders · 4.58M shares
#1 Rubric Capital Management LP 1.19M shares
#2 VANGUARD CAPITAL MANAGEMENT LLC 707.4K shares
#3 Clearline Capital LP 635.2K shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest56.5K
Days to Cover1.6
% of Float0.6%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Dec 31, 2023
xbrl XBRL CONVERTIBLE Dec 31, 2012
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for TXMD Shareholders

TherapeuticsMD, Inc. (TXMD) has a DilutionScore of 65/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 14, 2026, updated from SEC EDGAR data.

DilutionWatch tracks 6.5M outstanding warrants for TXMD. Warrants become dilutive when exercised — converting to common shares at the strike price. Warrants near or in-the-money deserve particular attention since exercise can add materially to the outstanding share count within a short window. Cash runway is a key watch item: TXMD has approximately 1 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for TXMD in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for TXMD alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.

Warrants Explained →
Track TXMD Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking TXMD — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for TXMD
📊 TXMD FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 TXMD Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.